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Abstract
Background: It is well known that methamphetamine (METH) is neurotoxic and recent studies have suggested the
involvement of neuroinflammatory processes in brain dysfunction induced by misuse of this drug. Indeed, glial cells
seem to be activated in response to METH, but its effects on microglial cells are not fully understood. Moreover, it has
been shown that cytokines, which are normally released by activated microglia, may have a dual role in response to
brain injury. This led us to study the toxic effect of METH on microglial cells by looking to cell death and alterations of
tumor necrosis factor-alpha (TNF-α) and interleukine-6 (IL-6) systems, as well as the role played by these cytokines.
Methods: We used the N9 microglial cell line, and cell death and proliferation were evaluated by terminal
deoxynucleotidyl transferase dUTP nick end labeling assay and incorporation of bromodeoxyuridine, respectively. The
TNF-α and IL-6 content was quantified by enzyme-linked immunosorbent assay, and changes in TNF receptor 1, IL-6
receptor-alpha, Bax and Bcl-2 protein levels by western blotting. Immunocytochemistry analysis was also performed to
evaluate alterations in microglial morphology and in the protein expression of phospho-signal transducer and activator
of transcription 3 (pSTAT3).
Results: METH induced microglial cell death in a concentration-dependent manner (EC50=1 mM), and also led to
significant morphological changes and decreased cell proliferation. Additionally, this drug increased TNF-α extracellular
and intracellular levels, as well as its receptor protein levels at 1 h, whereas IL-6 and its receptor levels were increased at
24 h post-exposure. However, the endogenous proinflammatory cytokines did not contribute to METH-induced
microglial cell death. On the other hand, exogenous low concentrations of TNF-α or IL-6 had a protective effect.
Interestingly, we also verified that the anti-apoptotic role of TNF-α was mediated by activation of IL-6 signaling,
specifically the janus kinase (JAK)-STAT3 pathway, which in turn induced down-regulation of the Bax/Bcl-2 ratio.
Conclusions: These findings show that TNF-α and IL-6 have a protective role against METH-induced microglial
cell death via the IL-6 receptor, specifically through activation of the JAK-STAT3 pathway, with consequent
changes in pro- and anti-apoptotic proteins.
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Methamphetamine (METH) is a potent addictive psy-
chostimulant drug that easily crosses the blood–brain
barrier and induces severe brain damage, leading to
neurological abnormalities and eventually to psychiatric
disorders. Several studies have demonstrated that people
who misuse METH reveal deficits in the dopaminergic
and serotonergic systems, hippocampal volume reduc-
tion, white-matter hypertrophy and microglia activation
[1-3]. However, the underlying mechanisms of its toxicity
remain to be fully determined. Nevertheless, oxidative
stress [4,5], excitotoxicity [6,7], mitochondrial dysfunc-
tion [5,8], and microgliosis [9,10] are some features of
METH neurotoxicity. Recently, our group have demon-
strated that a single high dose of METH (30 mg/kg by
intraperitoneal injection (i.p.)) triggered a neuroinflam-
matory response in mouse hippocampus, characterized
by the activation of microglia and production of proin-
flammatory cytokines, namely TNF-α [9,11] and IL-6
[11]. In agreement, Thomas et al. [12] showed that
microglial activation is a specific marker for METH
neurotoxicity being linked to dopamine or serotonin
(5-hydroxytryptamine) nerve terminal damage. How-
ever, the attenuation of microglial activation is not by
itself sufficient to protect against METH-induced stri-
atal dopaminergic neurotoxicity [13], and this lack of
neuroprotection was shown to be due to the inability
of minocycline to modulate TNF-α signaling. More-
over, Thomas and collaborators [14] concluded that
microglial-specific fractalkine receptor (CX3CR1) sig-
naling does not modulate METH neurotoxicity or
microglial activation.
It is known that after a central nervous system injury,
microglial cells became activated and, besides morpho-
logical alteration, they get the capacity to produce and
release high levels of proinflammatory cytokines [9,15].
These high levels could cause the microglial cells to shift
from having a beneficial role to a detrimental one [16].
Moreover, the action of some cytokines can stimulate
the synthesis and function of others, resulting in a com-
plex pathway called cytokine cascade [17]. Specifically,
TNF-α has been reported as a potent stimulator of IL-6
production [18,19], whose pleiotropic action can be
through TNF receptor 1 (TNFR1/p55) or 2 (TNFR2/p75)
[20]. The activation of TNF receptors stimulates several
signaling pathways that regulate cellular processes, ran-
ging from cell proliferation and differentiation to cell
death [21]. Regarding IL-6, its production seems to be
regulated by several signaling cascades [18,22], including
by TNF-α mainly via the nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) pathway
[23,24]. The growing interest in central IL-6 is in part
owing to its involvement in the neuroinflammatory re-
sponse [25] and neurotropic processes [26-28], as well as
in several brain pathologies [29,30]. This pleiotropic
cytokine acts through two receptors, the IL-6 receptor-
alpha (IL-6R-α, also known as gp80 or CD126) and a sol-
uble form of the IL-6R [31]. When IL-6 binds to its re-
ceptor, homodimerization of gp130 occurs, followed by
the activation of associated janus kinases (JAKs) [32],
and the recruitment of signal transducer and activator of
transcription (STAT) proteins to the nucleus, where they
will modulate gene transcription [33]. In vitro and
in vivo studies showed that IL-6 signaling in the central
nervous system is carried out by STAT3 that is phos-
phorylated by JAK at Tyr705 [34,35].
Regarding the effect of METH on proinflammatory cyto-
kines, Ladenheim et al. [36] showed that the IL-6 null
genotype affords protection to dopamine and serotonin
terminal damage, apoptotic cell death, and reactive gliosis
induced by METH (four i.p. injections of 5 or 10 mg/kg).
More recently Tocharus et al. [37] reported that METH
reduced rat microglial cells viability simultaneously with
the increase of IL-6 and TNF-α expression and the pro-
duction of both reactive oxygen species and reactive nitro-
gen species, suggesting that cytokines may also participate
in METH toxicity. Despite these pieces of evidence, it
remains to be clarified whether neuroinflammation and
the consequent synthesis and release of proinflammatory
cytokines is a cause or consequence of the neurotoxicity
induced by METH.
The present study aimed to determine whether METH
exerts a direct effect on microglial cells and to unravel the
beneficial or detrimental role of IL-6 and TNF-α.W e
found that METH induces microglial cell death, and also
affects microglial morphology and proliferation. Addition-
ally, this drug increased the protein levels of both cyto-
kines and respective receptors. Moreover, the release of
TNF-α and IL-6 observed after METH insult was shown
to be a consequence of METH toxicity and not a cause.
Interestingly, we also demonstrated that exogenous low
levels of both cytokines have a protective role against
METH toxicity through activation of the IL-6/JAK-STAT3
signaling pathway and, consequently, alterations in the
levels of pro- and anti-apoptotic proteins. The present
work allows us to better understand how METH affects
the microglia dynamics and suggest that the IL-6 system is
an important target to prevent, or at least to minimize, the
toxic effects of METH.
Methods
Cell culture
The murine microglial cell line N9 (kindly provided by Prof.
Claudia Verderio, CNR Institute of Neuroscience, Cellular
and Molecular Pharmacology, Milan, Italy) was obtained by
immortalization of E13 mouse embryonic brain cultures
with the 3RV retrovirus carrying an activated v-myc onco-
gene [38]. Cells were cultured in Roswell Park Memorial
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with 5% Fetal Bovine Serum (FBS; Gibco), 23.8 mM sodium
bicarbonate (Sigma-Aldrich, St. Louis, MO, USA), 30 mM
D-Glucose (Sigma-Aldrich), 100 U/mL penicillin and
100 μg/mL streptomycin (Gibco), and were maintained at
37 °C, 95% air and 5% CO2 in a humidified incubator. N9
cells were then seeded onto 24-well plates with 1.6×10
4
cells/well for terminal deoxynucleotidyl transferase dUTP
nick end labeling (TUNEL) assay, 5-bromo-2’-deoxyuridine
(BrdU) incorporation and immunocytochemistry; 12-well
plates with 5.6×10
4 cells/well for ELISA; and 6-well plates
with 5×10
5 cells/well for western blotting.
TUNEL assay
N9 cells were incubated with increasing concentrations (0.1
to 4 mM) of METH ((+)-methamphetamine hydrochloride;
Sigma-Aldrich) for 24 h. The present concentration range
of METH was chosen based on previous in vitro studies
[37,39,40]. In order to confirm cell death by apoptosis,
microglial cells were co-incubated for 24 h with 1 mM
METH plus z-Val-Ala-DL-Asp (OMe)-fluoromethylketone
(Z-VAD; Calbiochem, Nottingham, UK) at a concentration
of 25 μM that was chosen based on prior works developed
by our group [41,42].
To investigate the contribution of endogenous and ex-
ogenous TNF-α, N9 cells were co-incubated with
100 μg/mL anti-TNF-α antibody (Upstate Biotechnology,
Inc., Lake Placid, NY, USA) or 1 ng/mL TNF-α (R&D
systems, Abingdon, UK) plus 1 mM METH over 24 h.
The role played by endogenous IL-6 in METH-induced
cell death was investigated by pre-exposing the cells to
10 μg/mL anti-IL-6R antibody (R&D systems) for 20 min
or 20 μM AG490 (Calbiochem) for 1 h, and then co-
incubated with 1 mM METH. To analyze the effect of
exogenous IL-6, cells were co-exposed to 1 ng/mL IL-6
(R&D systems) plus 1 mM METH for 24 h, in the ab-
sence or presence of IL-6R antibody or 20 μM AG490,
as mentioned above. Moreover, in an attempt to clarify
the crosstalk between these cytokines in METH-induced
apoptosis, N9 cells were pre-incubated for 20 min with
IL-6R antibody and then co-incubated for 24 h with
1 ng/mL TNF-α plus 1 mM METH. Anti-TNF-α anti-
body and anti-IL-6R antibody were used at 100 μg/mL
or 10 μg/mL to neutralize the effects of 1 ng/mL TNF-α
[41,43] or 1 ng/mL IL-6, respectively (in agreement with
the instruction of the supplier). Tyrphostin AG 490 has
been successfully used to inhibit the activation of STAT3
in microglia cells [44,45], and we chose the concentra-
tion of 20 μM based on previous studies [45,46].
After the respective treatments, we collected the super-
natant that contained cells that had detached from the
bottom of the wells (dead or dying cells). Adherent cells
(surviving cells) were trypsinized and added to the
detached cells in order to obtain the whole population of
cells. Then, microglial cells were fixed with 4% parafor-
maldehyde (PFA) and adhered to superfrost microscope
slides (Thermo Scientific, Menzel GmbH & Co KG,
Braunschweig, Germany) by centrifugation (113×g,
5 min; Cellspin I, Tharmac GmbH, Waldsolms, Ger-
many). Apoptotic cell death was further evaluated by the
TUNEL assay (Roche Diagnostics GmbH, Mannheim,
Germany), as follows. Cells were rinsed with 0.01 M PBS
(137 mM sodium chloride, 2.7 mM potassium chloride,
4.3 mM disodium hydrogen phosphate, 1.47 mM mono-
potassium dihydrogen phosphate, pH 7.4), permeabilized
in 0.25% Triton X-100 for 30 min at room temperature
(RT), and incubated with terminal deoxynucleotidyl
transferase buffer for 1 h at 37 °C in a humidified cham-
ber. Afterwards, N9 cells were washed in terminal buffer
(300 mM sodium chloride and 30 mM sodium citrate)
for 15 min and in 0.01 M PBS for 5 min. Incubation with
fluorescein Avidin D (1:100; Vector Laboratories, Burlin-
game, CA, USA) was performed for 1 h, followed by nu-
clei counterstaining with 5 μg/ml Hoechst 33342 (Sigma-
Aldrich) for 5 min. The slides were mounted in Dako
fluorescent medium (Dako North America Inc., Carpin-
teria, CA, USA) and fluorescent images for cell counts
were recorded using an Axiovert 200 M fluorescence
microscope (Carl Zeiss, Oberkochen, Germany).
Immunocytochemistry
Microglial cells were exposed to 1 mM METH for 24 h
and then rinsed with 0.01 M PBS, fixed with 4% PFA for
30 min at RT, permeabilized with acetone for 3 min at
−20 °C and blocked with 0.01 M PBS containing 10%
FBS for 1 h at RT. Afterwards, cells were incubated with
the polyclonal antibody ionized calcium binding adaptor
molecule-1 (Iba-1; 1:400; Abcam, Cambridge, MA, USA)
overnight at 4 °C and then incubated with Alexa Fluor
488 anti-goat (1:200; Invitrogen, Paisley, UK) together
with rhodamine phalloidin (1:200, Molecular Probes,
Invitrogen) for 1 h 30 min at RT, which allowed the
visualization of F-actin filaments. To evaluate STAT3 ac-
tivation, cells were exposed to 1 mM METH alone or
co-exposed with 1 ng/mL IL-6 for 24 h. After treatment,
cells were rinsed with 0.01 M PBS, fixed with 4% PFA
for 30 min at RT, permeabilized with 0.5% Triton X-100
for 30 min at RT, blocked with PBS containing 1% BSA
for 1 h at RT, and incubated with the monoclonal anti-
body phosphorylated (p)-STAT3 (1:100; Cell Signaling
Technology, Inc., Danvers, MA, USA) overnight at 4 °C.
Cells were then incubated with Alexa Fluor 594 donkey
anti-mouse (1:200; Invitrogen) for 1 h 30 min at RT and
stained with Hoechst 33342 (4 μg/mL; Sigma-Aldrich)
for 5 min at RT in the dark. Finally, cultures were
mounted in Dako fluorescence medium (Dako North
America Inc.) and images were captured using a LSM
Coelho-Santos et al. Journal of Neuroinflammation 2012, 9:103 Page 3 of 14
http://www.jneuroinflammation.com/content/9/1/103710 Meta confocal microscope (Carl Zeiss, Göttingen,
Germany).
Cell proliferation studies
Cell proliferation was evaluated by BrdU (Sigma-Aldrich)
incorporation based on previous work [47]. Microglial
cells were treated with METH (0.001 to 1 mM) and/or
25 μM Z-VAD for 24 h; 10 μM BrdU was added in the
last 2 h of the culture session. Cells were then fixed in
4% PFA for 30 min and rinsed in 0.01 M PBS. BrdU was
unmasked by successive passages in 1% Triton X-100 for
30 min, ice-cold 0.1 M hydrogen chloride for 20 min,
and 2 M hydrogen chloride for 40 min at 37 °C, follow-
ing neutralization with 0.1 M hydrous sodium borate
buffer (pH 8.5; Sigma-Aldrich) for 10 min at RT and in-
cubation in a blocking solution with 3% BSA (Sigma-
Aldrich) and 0.3% Triton X-100 in 0.01 M PBS for
30 min at RT. Afterwards, microglial cells were incu-
bated with rat anti-BrdU (1:100; AbD Serotec, Oxford,
UK) in 0.01 M PBS containing 0.3% Triton X-100 and
0.3% BSA, overnight at 4 °C, and then with Alexa Fluor
488 (1:200; Invitrogen) for 1 h 30 min at RT, followed by
cell nuclei counterstaining with 4 μg/ml Hoechst 33342
for 5 min at RT. Cells were mounted in Dako fluorescent
medium (Dako North America Inc.) and images were
recorded using a camera Leica DMIRE2 incorporated on
a fluorescence microscope (Leica CTRMIC; Leica Micro-
systems, Wetzlar, Germany).
Enzyme-linked immunosorbent assay
To evaluate the intracellular and extracellular contents of
TNF-α and IL-6, cells were treated with 1 mM METH or
1 μg/mL lipopolysaccharide (LPS; positive control) for 1 h
or 24 h followed by ELISA assay (Bender MedSystem
W,V i -
enna, Austria). For that purpose, the supernatant was
removed and centrifuged for 15 min at 17,968×g at 4 °C,
and then cells were lysed using a specific buffer (pH 8.0)
as follows: 150 mM sodium chloride, 10 mM Tris-hydro-
gen chloride, 10% Triton X-100, 1 mM ethylenediaminete-
traacetic acid complemented by a protease inhibitor
cocktail tablet (Roche Applied Sciences, Basel, Switzer-
land). Cells were then sonicated, and protein concentra-
tion was determined by the bicinchoninic acid method,
and stored at −20 °C until further use. ELISA assay was
then performed according to manufacturers' instructions.
Briefly, 96-well microtiter plates were coated with capture
antibody (5 μg/mL), sealed and left overnight at 4 °C.
Then, wells were washed with 0.01 M PBS plus 0.05%
Tween 20, blocked with 0.01 M PBS plus 0.5% BSA and
0.05% Tween 20, and left overnight at 4 °C. Next, N9 cell
culture samples and biotin-conjugated antibodies (1:1,000)
were added to all wells, and incubated at RT for 2 h on a
microplate shaker (200 rpm). After washing, streptavidin-
horseradish protein (1:5,000) was added and kept once
again at RT on a microplate shaker (200 rpm) for 1 h.
After washing, tetramethylbenzidine substrate solution
(eBioscience, Vienna, Austria) was added to each well for
10 to 20 min at RT. The reaction was stopped by adding
1 M phosphoric acid, and the absorbance was measured
with a microplate reader (Biotek, Synergy HT, Winooski,
USA), using a sample wavelength fixed at 450 nm and a
reference wavelength at 655 nm. A standard curve for
both cytokines was used to calculate the respective extra-
cellular (pg/mL) and intracellular (pg/mg of total protein)
protein levels.
Western blot analysis
Cells were exposed for 1 h or 24 h to 1 mM METH, co-
exposed with 1 mM METH and 1 ng/mL IL-6 for 24 h,
or pre-exposed with 20 μM AG 490 for 1 h followed by
incubation with 1 mM METH for 24 h. After treatment,
cells were lysed on ice in radioimmunoprecipitation
assay (RIPA) buffer (0.15 M sodium chloride, 0.05 M
Tris-base, 0.005 M ethyleneglycoltetraacetic acid, 0.5%
sodium deoxycholate, 0.1% SDS and 1% X-Triton, pH
7.5) supplemented with protease inhibitor cocktail
tablets (Roche Applied Sciences), quantified using the
bicinchoninic acid method, and stored at −20 °C until
further use. Total proteins (TNFR1, 40 μg; IL-6R-α,
25 μg; Bcl-2 and Bax, 30 μg) were separated by electro-
phoresis on SDS polyacrylamide gel, transferred onto
polyvinylidene difluoride membrane (Millipore, Madrid,
Spain), and then blocked with 5% non-fat milk (TNFR1,
IL-6R-α and Bcl-2 proteins) or 4% BSA (Bax protein) for
1 h at RT. Afterwards, the membranes were incubated
overnight at 4 °C with the primary antibodies as follows:
rabbit anti-TNFR1 (1:200, Santa Cruz Biotechnology,
Santa Cruz, CA,USA), goat anti-IL-6R-α (1:500, R&D
Systems), mouse anti-Bcl-2 (1:200, Santa Cruz Biotech-
nology) and rabbit anti-Bax (1:100, Santa Cruz Biotech-
nology). Then, membranes were washed and incubated
for 1 h at RT with alkaline phosphatase conjugated sec-
ondary antibody (anti-goat and anti-mouse-1:10,000;
anti-rabbit-1:20,000; Amersham, GE Healthcare Life Sci-
ence, Little Chalfont, Buckinghamshire, UK) and visua-
lized using ECF reagent (Amersham) on Typhoon FLA
9000 (GE Healthcare Bio-Sciences AB, Uppsala, Sweden).
Immunoblots were reprobed with β-actin antibody
(1:10,000, Sigma-Aldrich) to ensure equal sample load-
ing, and densitometric analyses were performed using
the ImageQuant version 5.0 software.
Statistical analysis
Results are expressed as mean±standard error of the
mean (SEM). Data were analyzed using the one-tailed
Mann–Whitney test for comparison between two
groups, or multiple level analysis of variance (ANOVA)
followed by Dunnett’s or Bonferroni’s post hoc test, as
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using GraphPad Prism 5.0 (GraphPad Software, San
Diego, CA, USA). The level of significance was P <0.05.
For the quantification of TUNEL and BrdU-positive
cells, six independent microscopy fields per coverslip
with 200× or 400× magnification were acquired, respect-
ively, and results are expressed as percentages of total
cells stained with Hoechst 33342 per each field (n=num-
ber of fields). For western blot and ELISA assay, n corre-
sponds to the number of independent experiments.
Results
Effect of METH on microglia: Cell death, morphological
changes and proliferation
It has been previously suggested that microglia activation
contributes to METH-related neuropathology [10], but
there is no evidence concerning the direct effect of this
drug on microglial cells. Thus, in the present study we
aimed to clarify if METH induces microglial cell death.
For that purpose, we exposed N9 microglial cells to differ-
ent concentrations of METH (0.1 to 4 mM) over 24 h, and
apoptotic cell death was evaluated by TUNEL assay. We
observed that METH significantly increases the number of
apoptotic cells in a concentration-dependent manner
(Figure 1A, B). Specifically, at a lower concentration there
was no significant difference when compared to control
(control: 0.90±0.12%, n=49; 0.1 mM METH: 1.06±0.28%
of total cells, n=10; Figure 1A). However, at concentra-
tions above 0.5 mM there was an increase of cell death as
follows: 0.5 mM: 12.63±1.21% of total cells, n=10; 1 mM:
36.44±1.21%, n=37; 2 mM: 69.12±2.53%, n=10; 4 mM:
85.75±1.84% of total cells, n=10 (Figure 1A, B). Based on
these results, we chose to use 1 mM of METH (EC50)i n
the subsequent studies reported in this manuscript. More-
over, in order to confirm that METH triggers microglial
apoptosis, cells were co-exposed to the drug (1 mM) plus
Z-VAD (25 μM), a cell-permeant pan caspase inhibitor.
We concluded that Z-VAD alone did not have any effect
(2.14±0.42% of total cells, n=20; Figure 1A), but was
able to completely prevent cell death induced by
1 mM METH (3.8±0.53% of total cells, n=20;
Figure 1A).
To evaluate possible morphological changes in surviving
cells, we performed Iba-1 and F-actin staining (Figure 2).
Untreated N9 microglia cultures showed considerable
ramifications, particularly lamellipodium- and filopodium-
like structures, indicating a surveillance state. However,
METH led to an arrangement of the actin cytoskeleton
and cells acquired a round shape with retracted filopodia
characteristic of microglia activation (Figure 2). In addition
Figure 1 METH induces microglial cell death. (A) METH increased the number of TUNEL-positive cells in a concentration-dependent manner
(0.1 to 4 mM for 24 h), and Z-VAD (25 μM) completely prevented the apoptotic cell death induced by 1 mM METH. The results are expressed as
percentage of total cells±SEM (n=10 to 25).
***P <0.001, Dunnett’s multiple comparison test, significantly different when compared to control.
+++P <0.001 to Bonferroni’s multiple comparison test, significantly different comparing with 1 mM METH. (B) Representative fluorescence images
of TUNEL-positive cells following treatment with 0.1, 1 or 4 mM METH. Scale bar, 20 μm. METH: methamphetamine; SEM: standard error of the
mean; TUNEL: terminal deoxynucleotidyl transferase mediated dUTP nick end labeling assay; Z-VAD: z-Val-Ala-DL-Asp (OMe)-fluoromethylketone.
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crease of Iba-1 immunoreactivity induced by METH
(Figure 2).
The effect of METH on microglial proliferation was
also studied. We found that low concentrations of
METH (0.001 and 0.01 mM) increased microglia prolif-
eration (control: 49.45±2.65%, n=33; 0.001 mM METH:
71.10±1.80%, n=23; 0.01 mM METH: 74.27±1.83% of
total cells, n=24; Figure 3). On the other hand, higher
concentrations of METH decreased cell proliferation, to
16.61±1.20% (n=21) with 0.1 mM METH and
13.15±0.90% of total cells (n=35) with 1 mM METH
(Figure 3). It is noteworthy that 0.1 mM METH did not
induce cell death, which demonstrates that METH also
has a negative impact on microglial proliferation. More-
over, since 1 mM METH induced cell death we further
co-exposed the cells with Z-VAD to clarify if the de-
crease in the number of BrdU-positive cells was due to
cell death instead of a direct effect on proliferation.
Interestingly, Z-VAD reduced, but not completely, the ef-
fect of METH (35.45±3% of total cells, n=10; Figure 3)
showing that this toxic concentration negatively affects
both cell viability and proliferation.
METH-induced alterations on microglial TNF-α and IL-6
systems
Microglia activation by inflammatory stimuli increases
the synthesis of proinflammatory cytokines such as TNF-
α and IL-6 [48]. To evaluate the possible changes in
microglial TNF-α and IL-6 systems triggered by METH,
we measured the released and intracellular levels of these
cytokines by ELISA at 1 h and 24 h after drug exposure.
Regarding TNF-α,w eo b s e r v e dt h a tf o l l o w i n g1ho f
METH exposure, both extracellular (Figure 4A) and intra-
cellular (Figure 4B) levels were significantly increased to
1,265±244.4 pg/mL (n=5) and 2,692.0±287.3 pg/mg of
total protein (n=13) respectively when compared with
control (extracellular: 132.2±43.1 pg/mL, n=8; intracellu-
lar: 1,032±214.3 pg/mg of total protein, n=7; Figure 4A,
B). Moreover, after 24 h there were no changes in the
extracellular levels (124.8±12.36 pg/mL, n=3; Figure 4C)
when comparing to control (76.95±1.76 pg/mL, n=3;
Figure 4C), but there was an increase of the intracellular
levels (control: 473.60±12.59 pg/mg total protein, n=3;
1 mM METH: 946.4±68.89 pg/mg total protein, n=3;
Figure 4D). As expected, 1 μg/mL LPS increased both
extracellular (900.3±146.4 pg/mL, n=8; Figure 4A) and
intracellular TNF-α levels (5,597±726.4 pg/mg of total
protein, n=8; Figure 4B) at 1 h post-METH exposure, but
after 24 h there was only a significant increase in the
Figure 2 METH causes microglial activation and cytoskeleton re-organization. Representative confocal images of F-actin (red) and Iba-1
immunoreactivity (green) in N9 microglial cells under control conditions and exposed to 1 mM METH. Cells were also stained with Hoechst 33342
(blue). Scale bar, 20 μm and 50 μm. Iba-1: ionized calcium binding adaptor molecule-1; METH: methamphetamine.
Figure 3 METH affects microglial proliferation. METH increased
the number of BrdU-positive cells at 0.001 and 0.01 mM, but had a
negative effect at 0.1 and 1 mM. Z-VAD (25 μM) reduced, but did
not completely prevent, the decrease in the number of
BrdU-positive cells induced by METH. The results are expressed as
percentage of total cells±SEM (n=10 to 35).
***P <0.01,
***P <0.001,
Dunnett’s multiple comparison test, significantly different comparing
to control.
+++P <0.001, Bonferroni’s multiple comparison test,
significantly different comparing with 1 mM METH. BrdU:
5-bromo-2’-deoxyuridine; METH: methamphetamine; SEM: standard
error of the mean; Z-VAD: z-Val-Ala-DL-Asp
(OMe)-fluoromethylketone.
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Figure 4C).
The analysis of IL-6 levels showed that neither the
extracellular nor the intracellular content of this cytokine
was changed by 1 mM METH at 1 h after exposure
(Figure 5A, B). Extracellular levels were control:
460.8±47.96 pg/mL, n=15; METH; 486.6±55.99 pg/
mL, n=13; and LPS; 507.6±73.80 pg/mL, n=15
(Figure 5A). The intracellular content was control:
5,321±506.9 pg/mg, n=8; METH: 4,867±374.70 pg/mg,
n=9; and LPS: 4,487±691.40 pg/mg, n=8 (Figure 5B).
On the contrary, after 24 h there was a significant in-
crease of the release levels of IL-6 (Figure 5C) triggered
by 1 mM METH (1,403±192.80 pg/mL, n=4), as well as
by 1 μg/mL LPS (2,242 ±175.30 pg/mL, n=4). Interest-
ingly, there was also a very significant increase in the
intracellular content of this cytokine at 24 h after METH
exposure (151,711±15,479 pg/mg of total protein, n=4;
Figure 5D). This also occurred, albeit at a lower scale, in
the presence of 1 μg/mL LPS (74,502±6,564 pg/mg of
total protein, n=6), when compared with the control
(37,335±7,877 pg/mg of total protein, n=8; Figure 5D).
Since METH induced significant alterations in TNF-α
and IL-6 protein levels, we further investigated if METH
also interferes with the expression of the cytokine recep-
tors. By western blot analysis, we could observe a
significant increase in TNFR1 protein levels at 1 h post-
METH (1 mM) exposure to 164.10±13.04% of the con-
trol (n=6; Figure 6A), but no differences were verified
after 24 h (data not shown). Regarding IL-6R-α protein
levels, we only found a significant increase in the protein
levels of this cytokine at 24 h after drug treatment
(118.6±4.33% of the control, n=15; Figure 6B), without
alterations at 1 h (data not shown).
Here, we demonstrate that METH increases the extra-
cellular and intracellular levels of TNF-α and IL-6 in N9
microglial cells, together with the up-regulation of the
receptor protein levels, TNFR1 and IL-6R-α.
Effect of endogenous TNF-α and IL-6 on METH-induced
microglial cell death
The role of cytokines such as TNF-α and IL-6 in re-
sponse to brain injury remains unclear, in part due to its
dual role [25,29,43]. Thus, since we had shown that
METH increases TNF-α and IL-6 release, our next ap-
proach was to investigate the role of these endogenous
cytokines under METH-induced cell death. For that, we
quantified the number of TUNEL-positive cells in the
presence of TNF-α (Figure 7A) or IL-6R (Figure 7B) neu-
tralizing antibodies. We observed that 100 μg/mL TNF-α
antibody was not able to prevent cell death induced by
1 mM METH (control: 0.5±0.09%, n=84; METH:
Figure 4 METH triggers an early increase in TNF-α protein levels. The effect of 1 mM METH on the (A, C) extracellular and (B, D) intracellular
TNF-α levels was evaluated after (A, B) 1 h and (C, D) 24 h of drug exposure by ELISA. As a positive control we used 1 μg/mL LPS. Data are
expressed as mean±SEM of pg/mL for release and pg/mg of total protein for the intracellular levels (n=3 to 13).
**P <0.01,
***P <0.001, Dunnett’s
post-test, significantly different from control. ELISA: enzyme-linked immunosorbent assay; LPS: lipopolysaccharide; METH: methamphetamine;
SEM: standard error of the mean; TNF-α: tumor necrosis factor-alpha.
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of total cells, n=23; Figure 7A). Moreover, TNF-α antibody
per se did not induce microglial toxicity (2.5±0.68% of total
cells, n=13; Figure 7A). Accordingly, the neutralization of
endogenous IL-6 with IL-6R antibody (10 μg/mL) did not
change the number of apoptotic cells induced by 1 mM
METH alone (METH: 28.3±1.41%; METH+IL-6R anti-
body: 31.7±3.06% of total cells, n=23; Figure 7B). Interest-
ingly, the blockade of the JAK-STAT3 pathway by 20 μM
AG 490, a tyrosine kinase inhibitor that blocks the autoki-
nase activity of JAK and consequently the DNA binding of
STATs [49], exacerbated the cell death induced by METH
to 35.7±1.91% of total cells (n=18; Figure 7B). Moreover,
IL-6R antibody or AG 490 per se did not induce significant
cell death (IL-6R antibody: 0.4±0.15%, n=24; AG490:
0.86±0.29% of total cells, n=17; Figure 7B).
Overall, these results show that the blockade of en-
dogenous TNF-α or IL-6 signaling pathways was not able
Figure 5 METH increases IL-6 protein levels after 24 hours. METH did not interfere with the (A) extracellular and (B) intracellular levels of IL-6
when analyzed 1 h post-treatment. However, following 24 h of METH exposure there was a significant increase in the (C) extracellular and (D)
intracellular levels of IL-6. The treatment with (C, D) 1 μg/mL LPS was used as a positive control and up-regulated IL-6 levels after 24 h. Data are
expressed as mean±SEM of pg/mL for extracellular levels and pg/mg of total protein for intracellular levels (n=4-15).
*P <0.05,
**P <0.01,
***P <0.001, Dunnett’s post-test, significantly different from control. IL-6: interleukin-6; LPS: lipopolysaccharide; METH: methamphetamine; SEM:
standard error of the mean.
Figure 6 METH increases TNFR1 and IL-6R-α protein levels. Quantification of (A) TNFR1 and (B) IL-6R-α protein levels in N9 microglial cells at
1 h and 24 h post-METH exposure, respectively. Above the bars, representative western blot images of TNFR1 (55 kDa), IL-6R-α (63 kDa) and actin
(42 kDa) are shown. The results are expressed as mean percentage of control±SEM (n=3 to 15).
*P <0.05, Mann–Whitney post-test, significantly
different from control. IL-6R-α: interleukin-6 receptor-alpha; kDa: kiloDaltons; LPS: lipopolysaccharide; METH: methamphetamine; SEM: standard
error of the mean; TNFR1: tumor necrosis factor receptor 1.
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that the increase of TNF-α and IL-6 intracellular levels
and their release are a consequence and not a cause of
METH-induced microglia toxicity.
Protective effect of exogenous TNF-α and IL-6 against
microglial cell death induced by METH
The dual role of cytokines generally depends on the en-
vironment, concentration and stimuli duration [50].
Moreover, an insult usually triggers the production of
several cytokines that may operate as a cascade [17,51].
Thus, we also aimed to clarify the effect of exogenous
TNF-α and IL-6 on METH-induced cell death and the
possible interplay between these two cytokines. The con-
centrations used in the present study were chosen based
on previous studies [26,43], but nevertheless we started
by demonstrating that they are not toxic to N9 micro-
glial cells by themselves (control: 0.5±0.09%, n=17;
1 ng/mL; TNF-α: 0.7±0.14%, n=17, Figure 8A; 1 ng/mL
IL-6: 0.6±0.17%, n=26, Figure 8B). We then showed
that 1 ng/mL TNF-α completely prevented the cell death
induced by 1 mM METH (METH: 28.28±1.41% of total
cells, n=86; METH+TNF-α: 2.86±0.46% of total cells,
n=25; Figure 8A).
Our next goal was to clarify if the observed protective
effect of TNF-α occurred via IL-6 signaling. Thus, we
performed the same experiment but in the presence of
the IL-6R antibody, and under these conditions TNF-α
lost its protective effect (24.13±2.50% of total cells,
n=31; Figure 8A). Based on these observations, IL-6 sig-
naling seems to play an important protective role under
conditions of METH toxicity. So, we further evaluated
the direct effect of IL-6 (1 ng/mL) and concluded that
this cytokine decreased the number of TUNEL-positive
cells induced by 1 mM METH to 12.47±0.83% of total
cells (n=44; Figure 8B). Moreover, the blockade of IL-6R
by the neutralizing antibody (10 μg/mL IL-6R antibody)
abolished the protective effect of IL-6 (30.79±2.74% of
total cells, n=24; Figure 8B). Interestingly, the inhibition
of the JAK-STAT3 pathway by 20 μM AG 490 exacer-
bated the toxic effect of METH (35.7±1.37% of total of
cells, n=18; Figure 8B). To confirm the results above
described, particularly the protective role of IL-6 against
METH through the activation of the JAK-STAT3 path-
way, we performed an immunocytochemistry analysis for
pSTAT3. In Figure 8C, it is possible to observe that, fol-
lowing METH treatment, the pSTAT3 levels were
decreased, but in the presence of IL-6 there was a recov-
ery of STAT3 phosphorylation levels and also its trans-
location to the nucleus (Figure 8C). These observations
allow us to conclude that exogenous TNF-α is protective
against METH-induced microglial cell death and this ef-
fect was dependent on IL-6 signaling via JAK-STAT3
pathway activation.
The activation of the IL-6 signaling pathway induces
alteration in pro-and anti-apoptotic proteins
Several studies have reported that METH causes signifi-
cant changes in several pro-and anti-apoptotic proteins,
such as Bax, Bad, Bcl-2 and Bcl-XL [52,53]. Furthermore,
it has been shown that the JAK-STAT3 pathway is
involved in protective mechanisms, in part due to its role
in the transcription of anti-apoptotic genes [54]. Hence,
we aimed to evaluate if the IL-6 anti-apoptotic effect
observed in the present study could be mediated by the
up-regulation of anti-apoptotic proteins through the acti-
vation of the JAK-STAT3 pathway. For that, the Bax/Bcl-2
ratio was analyzed in microglial cells treated with 1 mM
METH alone or in the presence of 1 ng/mL IL-6. We veri-
fied that METH increased the Bax/Bcl-2 ratio to
149.8±9.34% of control (n=7; Figure 9), which is in agree-
ment with our previous results (Figure 1). Furthermore,
Figure 7 Endogenous TNF-α and IL-6 are not involved in METH-induced microglial cell death. The increase in the number of TUNEL-positive
cells induced by 1 mM METH (24 h) was not changed by (A) TNF-α antibody or (B) IL-6R antibody, and the JAK-STAT pathway inhibitor (20 μ AG 490)
exacerbated the toxic effect of METH. The results are expressed as mean percentage of total cells±SEM (n=17 to 84).
***P <0.001, Dunnett’s post-test,
significantly different when compared with control.
++ P <0.01, Bonferroni’s post-test, when compared with 1 mM METH. IL-6: interleukin 6; IL-6R:
interleukin 6 receptor; JAK-STAT: janus kinase-signal transducer and activator of transcription; METH: methamphetamine; SEM: standard error of the
mean; TNF-α: tumor necrosis factor-alpha; TNFR1: tumor necrosis factor receptor 1.
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control, n=6) to values similar to the control, which sup-
ports the hypothesis that the IL-6 signaling pathway med-
iates anti-apoptotic events. Additionally, to prove the
involvement of the JAK-STAT3 pathway on IL-6-induced
cell protection, we demonstrated that its inhibition by AG
490 (20 μM) led to a recovery of the Bax/Bcl-2 ratio to
levels similar to those observed in the presence of METH
(METH+IL-6+AG 490: 153.9±15.97% of control, n=6;
Figure 9). These data allow us to conclude that the effect
of IL-6 was mediated by JAK-STAT3 pathway activation,
which culminated in changes of pro-and anti-apoptotic
protein levels.
Discussion
It has been extensively described that METH triggers
neuronal dysfunction or/and death [1,9,55] and also the
activation of glial cells, namely microglia [3,9,10]. How-
ever, the role played by proinflammatory cytokines under
conditions of METH-induced microglial toxicity is
poorly understood. In the present study, we report that
METH induces microglial cell death and affects cell pro-
liferation. Furthermore, we also show morphologic
alterations in microglia, which are accompanied by an
increased in the release and intracellular levels of TNF-α
and IL-6. Moreover, for the first time, we demonstrate
that the up-regulation of these proinflammatory cyto-
kines does not contribute to METH-induced cell death,
and that exogenous TNF-α or IL-6 have a protective ef-
fect via activation of the JAK-STAT3 pathway, which in
turn leads to a decrease in the Bax/Bcl-2 ratio.
The involvement of inflammatory events, such as glio-
sis [9,10,13,14] and an increase in the production of
proinflammatory cytokines [9,11,13,37], has recently
been suggested to play an important role in METH-
induced brain dysfunction. Accordingly, our group
showed that a single high dose of METH (30 mg/kg; i.p.)
led to a rapid up-regulation of both IL-6 and TNF-α
Figure 8 Protective effect of exogenous TNF-α or IL-6 against METH-induced microglial cell death. (A) TNF-α (1 ng/mL) completely
prevented the increase of TUNEL-positive cells induced by METH; this was abolished by IL-6R antibody (10 μg/mL). (B) IL-6 (1 ng/mL) reduced the
number of TUNEL-positive cells, and once again the blockade of its receptor with IL-6R antibody abolished this effect. Also, the JAK-STAT3
inhibitor (20 μM AG 490) exacerbated METH toxicity. The results are expressed as mean percentage of total cells±SEM (n=17 to 41).
***P <0.001,
Dunnett’s multiple comparison test, significantly different when compared to control;
++P <0.01,
+++P <0.001, Bonferroni’s multiple comparison
test, significantly different when compared with 1 mM METH;
}}}P <0.001, Bonferroni’s multiple comparison test, significantly different when
compared with 1 mM METH plus TNF-α or IL-6. (C) Representative images of pSTAT3 immunoreactivity (red) in N9 microglial cells under control
conditions and exposed to 1 mM METH alone or in the presence of 1 ng/mL IL-6. Cells were also stained with Hoechst 33342 (blue). Scale bar,
20 μm and 50 μm. IL-6: interleukin 6; JAK-STAT: janus kinase-signal transducer and activator of transcription; METH: methamphetamine; pSTAT:
phospho-signal transducer and activator of transcription; SEM: standard error of the mean; TNF-α: tumor necrosis factor-alpha; TUNEL: terminal
deoxynucleotidyl transferase mediated dUTP nick end labeling assay.
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striatum [11]. Moreover, we also demonstrated that the
same METH treatment triggered a neuroinflammatory
response characterized by microgliosis and astrogliosis,
as well as by changes in TNF system protein levels [9].
Concerning in vitro studies, there is only one study that
has approached this issue by demonstrating that, in
highly aggressively proliferating immortalized microglial
cells, a non-toxic concentration of METH (0.8 mM, 6 h
exposure) increased IL-1β, TNF-α and IL-6 mRNA
levels, followed by production of reactive oxygen and ni-
trogen species [37]. Our data, besides showing that
METH can induce microglial cell death by apoptosis,
also verified that METH is able to significantly increase
the release and production of TNF-α and IL-6. More-
over, the protein levels of TNFR1 and IL-6R-α were also
up-regulated, demonstrating that this drug significantly
interferes with both proinflammatory cytokine systems.
Interestingly, we also found that these alterations oc-
curred at different time-points, since METH-evoked
TNF-α release occurred at 1 h, and IL-6 release occurred
at 24 h. This time-course raises the hypothesis that the
released of TNF-α may stimulate the release of IL-6. In
fact, it was demonstrated that TNF-α induces IL-6 pro-
duction by regulation of its transcription, mainly via
TNFR1 [19] through activation of mitogen activated pro-
tein kinase/extracellular signal-regulated kinases (MAPK/
ERK) and p38 pathways [18,19,24], or also by NFκB cas-
cade [23]. Furthermore, TNF-α is known as a priming
cytokine at the apex of inflammatory cascades in immune
cells [56]. In agreement, a recent study reported that TNF-
null microglia showed a drastic reduction of IL-6 produc-
tion in response to LPS stimulation [56]. Additionally,
Yamashita et al. [57], using a co-culture of adipocytes and
macrophages, demonstrated that LPS (1 ng/mL) up-regu-
lated IL-6 production, which was partially inhibited by
anti-TNF-α neutralizing antibody. Other in vitro studies
have shown that treatment with TNF-α might be an essen-
tial step to IL-6-induced neuroprotection [58], and that
TNF-α stimulation increases IL-6R and gp130mRNA ex-
pression [58,59]. In agreement with these observations, we
showed that TNF-α release evoked by METH preceded
the increase of both IL-6 and IL-6R protein levels.
After demonstrating that METH induces significant
alterations on microglial TNF-α and IL-6 systems, we
further aimed to clarify the role played by such cytokines
under conditions of METH-induced cell death. We veri-
fied that the blockade of endogenous TNF-α and IL-6
did not affect microglial cell death induced by METH,
which suggest that the up-regulation of cytokine release
is a consequence of METH toxicity and not a cause.
Interestingly, the application of a low concentration of
exogenous TNF-α completely prevented apoptotic cell
death induced by the drug. In fact, Nakajima et al. [60]
reported an up-regulation of rat striatal TNF-α levels fol-
lowing a repeated treatment with METH (2 mg/kg for
5 days, subcutaneously), which was associated with a
neuroprotective effect. Specifically, they showed that ex-
ogenous TNF-α (4 μg; intracerebroventricular adminis-
tration) blocked locomotor-stimulating and rewarding
effects of METH (4 mg/kg; four times at 2 h intervals),
and also decreased the extracellular levels of striatal
dopamine and potentiated its uptake into synaptosomes
[60]. Moreover, we demonstrated that the protective ef-
fect of TNF-α occurred via IL-6 signaling pathway, be-
cause using an antibody to neutralize the IL-6R or
blocking the pathway completely abolished the protective
effect.
To date, there is very little information regarding the
role of IL-6 under METH toxicity. Ladenheim et al. [36]
showed that, in IL-6 knockout mice, the neurotoxicity
induced by METH was attenuated. The authors demon-
strated that IL-6
(−/−) mice subjected to a repeated METH
treatment (5 or 10 mg/kg; four times at 2 h intervals, i.
p.) showed less depletion of dopamine levels and its
transporter binding, a reduction in serotonin levels, and
also inhibition of gliosis, when compared with wild-type
Figure 9 IL-6 prevents the increase of the Bax/Bcl-2 ratio
mediated by METH. Western blot analysis shows that IL-6
(1 ng/mL) was able to reduce the augmentation of the Bax/Bcl-2
ratio following METH exposure. Above the bars, representative
western blot images of Bax (21 kDa), Bcl-2 (26 kDa) and β-actin
(42 kDa) are shown. The results are expressed as mean
percentage of control±SEM (n=4 to 7).
*P <0.05, Dunnett’s
multiple comparison test, significantly different when compared
with control;
+P <0.05, Bonferroni’s multiple comparison test,
significantly different when compared with 1 mM METH. IL-6:
interleukin 6; kDa: kiloDaltons; METH: methamphetamine; SEM:
standard error of the mean.
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IL-6 against METH toxicity has never been addressed
before, some studies have clearly shown that IL-6 has a
protective role under excitotoxic conditions [26,61-63].
In fact, it was demonstrated that the neuroprotective ef-
fect mediated by IL-6 against N-methyl-d-aspartate-
induced apoptosis of cerebellar granule neurons involves
the suppression of intracellular Ca
2+ overload [61], and
was mediated by JAK-STAT3 and PI3K-AKT signaling
pathways [61-63]. In line with these observations, we fur-
ther showed that a low concentration of exogenous IL-6
provided a decrease in the number of apoptotic cells
induced by METH, and this effect was mediated via IL-
6R activation, since the receptor neutralizing antibody
completely blocked its effect. Unexpectedly, the use of
AG490 not only abolished the protective effect mediated
by IL-6 but also increased the number of apoptotic cells
when compared with METH by itself. This observation
can be explained by the fact that AG 490 blocked both
IL-6R-dependent and -independent activation of JAK-
STAT3 pathway. In fact, JAK-STAT3 signaling is import-
ant not only to stimulate cellular proliferation and differ-
entiation, but it also plays a central role in cell survival
and regeneration in response to several factors, including
cytokines [54]. Previous studies showed that STAT3 reg-
ulates the transcription of anti-apoptotic genes, such as
bcl-2 and bcl-xl [54]. Moreover, STAT3 can also activate
the expression of other proteins that belong to the in-
hibitor of apoptosis protein family, including surviving
[64] and cellular inhibitor of apoptosis 2 [65]. Accord-
ingly, here we demonstrated that METH increases the
Bax/Bcl-2 ratio and IL-6 is able to completely prevent
this effect. Furthermore, when we blocked the JAK-
STAT3 pathway, the Bax/Bcl-2 ratio returned to values
similar to those observed in the presence of METH.
These observations lead us to conclude that the protect-
ive effect induced by IL-6 against METH-induced micro-
glial cell death occurs through JAK-STAT3 pathway
activation, which in turn interferes with anti- and pro-
apoptotic proteins levels. Our results are also in agree-
ment, with the study performed by Cadet et al. [66], who
showed that overexpression of Bcl-2 protects immorta-
lized rat neural cells against METH-induced apoptosis.
Conclusions
Our results highlight the toxic effect of METH on micro-
glial cells since it induced cell death, affected microglial
proliferation and increased the release and intracellular
levels of TNF-α and IL-6. Interestingly, endogenous
cytokines per se did not affect METH-induced cell death,
which suggest that alterations in such systems are a con-
sequence rather than a cause of METH-induced micro-
glial apoptosis. Moreover, exogenous low concentrations
of TNF-α and IL-6 provided a protective effect via
activation of the JAK-STAT3 pathway, which in turn led
to changes in the levels of anti-and pro-apoptotic pro-
teins. Thus, our data suggest that IL-6 system is an im-
portant target to prevent or at least to minimize the
toxic effects of METH.
Abbreviations
ANOVA: analysis of variance; BrdU: 5-bromo-2’-deoxyuridine; BSA: bovine
serum albumin; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine
serum; Iba-1: ionized calcium binding adaptor molecule-1; IL-6: interleukin-6;
IL-6R-α: interleukin-6 receptor-alpha; i.p.: intraperitoneal; JAK-STAT3: janus
kinase-signal transducer and activators of transcription; kDA: kiloDaltons;
LPS: lipopolysaccharide; METH: methamphetamine; NF-kB: nuclear factor
kappa-light-chain-enhancer of activated B cells; PBS: phosphate-buffered
saline; PFA: paraformaldehyde; RT: room temperature; SEM: standard error of
the mean; TNF-α: tumor necrosis factor-alpha; TNFR1: tumor necrosis factor
receptor 1; TUNEL: terminal deoxynucleotidyl transferase dUTP nick end
labeling; Z-VAD: z-Val-Ala-Dl-Asp-(OMe)-fluoromethylketone.
Competing interests
The authors declare that they have no competing interests.
Acknowledgments
The authors thank Paulo Santos for the technical information to manipulate
the N9 cell line and Dr Teresa Oliveira for providing the pSTAT3 antibody.
This work was supported by Grant PTDC/SAU-FCF/098685/2008 (COMPETE
and FEDER funds) and Fellowship SFRH/BD/35893/2007 from Foundation for
Science and Technology (Portugal), co-financed by QREN.
Authors’ contributions
VCS and JG carried out all the experiments. VCS wrote the manuscript and
JG designed the figures. APS designed, supervised and secured the funding
of the present study. CFR revised the manuscript. All authors have read and
approved the final manuscript.
Received: 30 December 2011 Accepted: 29 May 2012
Published: 29 May 2012
References
1. Thompson PM, Hayashi KM, Simon SL, Geaga JA, Hong MS, Sui Y, Lee JY,
Toga AW, Ling W, London ED: Structural abnormalities in the brains of
human subjects who use methamphetamine. J Neurosci 2004,
24:6028–6036.
2. McCann UD, Kuwabara H, Kumar A, Palermo M, Abbey R, Brasic J, Ye W,
Alexander M, Dannals RF, Wong DF, Ricaurte GA: Persistent cognitive and
dopamine transporter deficits in abstinent methamphetamine users.
Synapse 2008, 62:91–100.
3. Sekine Y, Ouchi Y, Sugihara G, Takei N, Yoshikawa E, Nakamura K, Iwata Y,
Tsuchiya KJ, Suda S, Suzuki K, Kawai M, Takebayashi K, Yamamoto S,
Matsuzaki H, Ueki T, Mori N, Gold MS, Cadet JL: Methamphetamine causes
microglial activation in the brains of human abusers. J Neurosci 2008,
28:5756–5761.
4. Pubill D, Canudas AM, Pallas M, Camins A, Camarasa J, Escubedo E: Different
glial response to methamphetamine-and
methylenedioxymethamphetamine-induced neurotoxicity. Naunyn
Schmiedebergs Arch Pharmacol 2003, 367:490–499.
5. Wu CW, Ping YH, Yen JC, Chang CY, Wang SF, Yeh CL, Chi CW, Lee HC:
Enhanced oxidative stress and aberrant mitochondrial biogenesis in
human neuroblastoma SH-SY5Y cells during methamphetamine induced
apoptosis. Toxicol Appl Pharmacol 2007, 220:243–251.
6. Rocher C, Gardier AM: Effects of repeated systemic administration of
d-Fenfluramine on serotonin and glutamate release in rat ventral
hippocampus: comparison with methamphetamine using in vivo
microdialysis. Naunyn Schmiedebergs Arch Pharmacol 2001, 363:422–428.
7. Stephans SE, Yamamoto BK: Methamphetamine-induced neurotoxicity:
roles for glutamate and dopamine efflux. Synapse 1994, 17:203–209.
8. Brown JM, Quinton MS, Yamamoto BK: Methamphetamine-induced
inhibition of mitochondrial complex II: roles of glutamate and
peroxynitrite. J Neurochem 2005, 95:429–436.
Coelho-Santos et al. Journal of Neuroinflammation 2012, 9:103 Page 12 of 14
http://www.jneuroinflammation.com/content/9/1/1039. Gonçalves J, Baptista S, Martins T, Milhazes N, Borges F, Ribeiro CF, Malva JO,
Silva AP: Methamphetamine-induced neuroinflammation and neuronal
dysfunction in the mice hippocampus: preventive effect of
indomethacin. Eur J Neurosci 2010, 31:315–326.
10. LaVoie MJ, Card JP, Hastings TG: Microglial activation precedes dopamine
terminal pathology in methamphetamine-induced neurotoxicity. Exp
Neurol 2004, 187:47–57.
11. Goncalves J, Martins T, Ferreira R, Milhazes N, Borges F, Ribeiro CF, Malva JO,
Macedo TR, Silva AP: Methamphetamine-induced early increase of IL-6
and TNF-alpha mRNA expression in the mouse brain. Ann N Y Acad Sci
2008, 1139:103–111.
12. Thomas DM, Walker PD, Benjamins JA, Geddes TJ, Kuhn DM:
Methamphetamine neurotoxicity in dopamine nerve endings of the
striatum is associated with microglial activation. J Pharmacol Exp Ther
2004, 311:1–7.
13. Sriram K, Miller DB, O’Callaghan JP: Minocycline attenuates microglial
activation but fails to mitigate striatal dopaminergic neurotoxicity: role
of tumor necrosis factor-alpha. J Neurochem 2006, 96:706–718.
14. Thomas DM, Francescutti-Verbeem DM, Kuhn DM:
Methamphetamine-induced neurotoxicity and microglial activation are
not mediated by fractalkine receptor signaling. J Neurochem 2008,
106:696–705.
15. Streit WJ, Walter SA, Pennell NA: Reactive microgliosis. Prog Neurobiol 1999,
57:563–581.
16. Bernardino L, Malva JO: Inflammation and neuronal susceptibility to
excitotoxic cell death.I nInteraction Between Neurons and Glia in Aging and
Disease. Edited by Malva JO, Rego AC, Cunha RA, Oliveira CR. New York:
Springer US; 2007:3–35.
17. Vilcek J, Feldmann M: Historical review: cytokines as therapeutics and
targets of therapeutics. Trends Pharmacol Sci 2004, 25:201–209.
18. Leonard M, Ryan MP, Watson AJ, Schramek H, Healy E: Role of MAP kinase
pathways in mediating IL-6 production in human primary mesangial and
proximal tubular cells. Kidney Int 1999, 56:1366–1377.
19. Amrani Y, Ammit AJ, Panettieri RA Jr: Tumor necrosis factor receptor
(TNFR) 1, but not TNFR2, mediates tumor necrosis factor-alpha-induced
interleukin-6 and RANTES in human airway smooth muscle cells: role of
p38 and p42/44 mitogen-activated protein kinases. Mol Pharmacol 2001,
60:646–655.
20. Kinouchi K, Brown G, Pasternak G, Donner DB: Identification and
characterization of receptors for tumor necrosis factor-alpha in the brain.
Biochem Biophys Res Commun 1991, 181:1532–1538.
21. Baud V, Karin M: Signal transduction by tumor necrosis factor and its
relatives. Trends Cell Biol 2001, 11:372–377.
22. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper
F: Principles of interleukin (IL)-6-type cytokine signalling and its
regulation. Biochem J 2003, 374:1–20.
23. Sparacio SM, Zhang Y, Vilcek J, Benveniste EN: Cytokine regulation of
interleukin-6 gene expression in astrocytes involves activation of an
NF-kappa B-like nuclear protein. J Neuroimmunol 1992, 39:231–242.
24. Beyaert R, Cuenda A, Vanden Berghe W, Plaisance S, Lee JC, Haegeman G,
Cohen P, Fiers W: The p38/RK mitogen-activated protein kinase pathway
regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO
J 1996, 15:1914–1923.
25. Penkowa M, Giralt M, Carrasco J, Hadberg H, Hidalgo J: Impaired
inflammatory response and increased oxidative stress and
neurodegeneration after brain injury in interleukin-6-deficient mice. Glia
2000, 32:271–285.
26. Pizzi M, Sarnico I, Boroni F, Benarese M, Dreano M, Garotta G, Valerio A,
Spano P: Prevention of neuron and oligodendrocyte degeneration by
interleukin-6 (IL-6) and IL-6 receptor/IL-6 fusion protein in organotypic
hippocampal slices. Mol Cell Neurosci 2004, 25:301–311.
27. Hakkoum D, Stoppini L, Muller D: Interleukin-6 promotes sprouting and
functional recovery in lesioned organotypic hippocampal slice cultures. J
Neurochem 2007, 100:747–757.
28. Islam O, Gong X, Rose-John S, Heese K: Interleukin-6 and neural stem cells:
more than gliogenesis. Mol Biol Cell 2009, 20:188–199.
29. Quintanilla RA, Orellana DI, Gonzalez-Billault C, Maccioni RB: Interleukin-6
induces Alzheimer-type phosphorylation of tau protein by deregulating
the cdk5/p35 pathway. Exp Cell Res 2004, 295:245–257.
30. Pavelko KD, Howe CL, Drescher KM, Gamez JD, Johnson AJ, Wei T,
Ransohoff RM, Rodriguez M: Interleukin-6 protects anterior horn neurons
from lethal virus-induced injury. J Neurosci 2003, 23:481–492.
31. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S: The pro- and anti-
inflammatory properties of the cytokine interleukin-6. Biochim Biophys
Acta 2011, 1813:878–888.
32. Murakami M, Hibi M, Nakagawa N, Nakagawa T, Yasukawa K, Yamanishi K,
Taga T, Kishimoto T: IL-6-induced homodimerization of gp130 and
associated activation of a tyrosine kinase. Science 1993, 260:1808–1810.
33. Ihle JN: STATs: signal transducers and activators of transcription. Cell
1996, 84:331–334.
34. Jenab S, Quinones-Jenab V: The effects of interleukin-6, leukemia
inhibitory factor and interferon-gamma on STAT DNA binding and c-fos
mRNA levels in cortical astrocytes and C6 glioma cells. Neuro Endocrinol
Lett 2002, 23:325–328.
35. Sanz E, Hofer MJ, Unzeta M, Campbell IL: Minimal role for STAT1 in
interleukin-6 signaling and actions in the murine brain. Glia 2008,
56:190–199.
36. Ladenheim B, Krasnova IN, Deng X, Oyler JM, Polettini A, Moran TH, Huestis
MA, Cadet JL: Methamphetamine-induced neurotoxicity is attenuated in
transgenic mice with a null mutation for interleukin-6. Mol Pharmacol
2000, 58:1247–1256.
37. Tocharus J, Khonthun C, Chongthammakun S, Govitrapong P: Melatonin
attenuates methamphetamine-induced overexpression of
pro-inflammatory cytokines in microglial cell lines. J Pineal Res 2010,
48:347–352.
38. Righi M, Mori L, De Libero G, Sironi M, Biondi A, Mantovani A, Donini SD,
Ricciardi-Castagnoli P: Monokine production by microglial cell clones. Eur J
Immunol 1989, 19:1443–1448.
39. Aizenman E, McCord MC, Saadi RA, Hartnett KA, He K: Complex role of zinc
in methamphetamine toxicity in vitro. Neuroscience 2010, 171:31–39.
40. Nopparat C, Porter JE, Ebadi M, Govitrapong P: The mechanism for the
neuroprotective effect of melatonin against methamphetamine-induced
autophagy. J Pineal Res 2010, 49:382–389.
41. Bernardino L, Agasse F, Silva B, Ferreira R, Grade S, Malva JO: Tumor
necrosis factor-alpha modulates survival, proliferation, and neuronal
differentiation in neonatal subventricular zone cell cultures. Stem Cells
2008, 26:2361–2371.
42. Bento AR, Baptista S, Malva JO, Silva AP, Agasse F: Methamphetamine
exerts toxic effects on subventricular zone stem/progenitor cells and
inhibits neuronal differentiation. Rejuvenation Res 2011, 14:205–214.
43. Bernardino L, Xapelli S, Silva AP, Jakobsen B, Poulsen FR, Oliveira CR, Vezzani
A, Malva JO, Zimmer J: Modulator effects of interleukin-1beta and tumor
necrosis factor-alpha on AMPA-induced excitotoxicity in mouse
organotypic hippocampal slice cultures. J Neurosci 2005, 25:6734–6744.
44. Huang C, Ma R, Sun S, Wei G, Fang Y, Liu R, Li G: JAK2-STAT3 signaling
pathway mediates thrombin-induced proinflammatory actions of
microglia in vitro. J Neuroimmunol 2008, 204:118–125.
45. Kim OS, Park EJ, Joe EH, Jou I: JAK-STAT signaling mediates
gangliosides-induced inflammatory responses in brain microglial cells. J
Biol Chem 2002, 277:40594–40601.
46. Gorina R, Sanfeliu C, Galito A, Messeguer A, Planas AM: Exposure of glia to
pro-oxidant agents revealed selective Stat1 activation by H2O2 and
Jak2-independent antioxidant features of the Jak2 inhibitor AG490. Glia
2007, 55:1313–1324.
47. Baptista S, Bento AR, Goncalves J, Bernardino L, Summavielle T, Lobo A,
Fontes-Ribeiro C, Malva JO, Agasse F, Silva AP: Neuropeptide Y promotes
neurogenesis and protection against methamphetamine-induced toxicity
in mouse dentate gyrus-derived neurosphere cultures.
Neuropharmacology 2012, 62:2412–2422.
48. Hanisch UK: Microglia as a source and target of cytokines. Glia 2002,
40:140–155.
49. De Vos J, Jourdan M, Tarte K, Jasmin C, Klein B: JAK2 tyrosine kinase
inhibitor tyrphostin AG490 downregulates the mitogen-activated protein
kinase (MAPK) and signal transducer and activator of transcription (STAT)
pathways and induces apoptosis in myeloma cells. Br J Haematol 2000,
109:823–828.
50. Deverman BE, Patterson PH: Cytokines and CNS development. Neuron
2009, 64:61–78.
51. Neta R, Sayers TJ, Oppenheim JJ: Relationship of TNF to interleukins.
Immunol Ser 1992, 56:499–566.
52. Deng X, Cai NS, McCoy MT, Chen W, Trush MA, Cadet JL:
Methamphetamine induces apoptosis in an immortalized rat striatal cell
Coelho-Santos et al. Journal of Neuroinflammation 2012, 9:103 Page 13 of 14
http://www.jneuroinflammation.com/content/9/1/103line by activating the mitochondrial cell death pathway.
Neuropharmacology 2002, 42:837–845.
53. Jayanthi S, Deng X, Bordelon M, McCoy MT, Cadet JL: Methamphetamine
causes differential regulation of pro-death and anti-death Bcl-2 genes in
the mouse neocortex. FASEB J 2001, 15:1745–1752.
54. Dziennis S, Alkayed NJ: Role of signal transducer and activator of
transcription 3 in neuronal survival and regeneration. Rev Neurosci 2008,
19:341–361.
55. Cadet JL, Jayanthi S, Deng X: Methamphetamine-induced neuronal
apoptosis involves the activation of multiple death pathways. Review.
Neurotox Res 2005, 8:199–206.
56. Harms AS, Lee JK, Nguyen TA, Chang J, Ruhn KM, Trevino I, Tansey MG:
Regulation of microglia effector functions by tumor necrosis factor
signaling. Glia 2012, 60:189–202.
57. Yamashita A, Soga Y, Iwamoto Y, Yoshizawa S, Iwata H, Kokeguchi S,
Takashiba S, Nishimura F: Macrophage-adipocyte interaction: marked
interleukin-6 production by lipopolysaccharide. Obesity (Silver Spring) 2007,
15:2549–2552.
58. Inoue K, Koizumi S, Tsuda M, Shigemoto-Mogami Y: Signaling of ATP
receptors in glia-neuron interaction and pain. Life Sci 2003, 74:189–197.
59. Marz P, Gadient RA, Otten U: Expression of interleukin-6 receptor (IL-6R)
and gp130 mRNA in PC12 cells and sympathetic neurons: modulation by
tumor necrosis factor alpha (TNF-alpha). Brain Res 1996, 706:71–79.
60. Nakajima A, Yamada K, Nagai T, Uchiyama T, Miyamoto Y, Mamiya T, He J,
Nitta A, Mizuno M, Tran MH, Seto A, Yoshimura M, Kitaichi K, Hasegawa T,
Saito K, Yamada Y, Seishima M, Sekikawa K, Kim HC, Nabeshima T: Role of
tumor necrosis factor-alpha in methamphetamine-induced drug
dependence and neurotoxicity. J Neurosci 2004, 24:2212–2225.
61. Yamada M, Hatanaka H: Interleukin-6 protects cultured rat hippocampal
neurons against glutamate-induced cell death. Brain Res 1994,
643:173–180.
62. Wang XC, Qiu YH, Peng YP: Interleukin-6 protects cerebellar granule
neurons from NMDA-induced neurotoxicity. Sheng Li Xue Bao 2007,
59:150–156.
63. Wang XQ, Peng YP, Lu JH, Cao BB, Qiu YH: Neuroprotection of
interleukin-6 against NMDA attack and its signal transduction by JAK
and MAPK. Neurosci Lett 2009, 450:122–126.
64. Haas CA, Hofmann HD, Kirsch M: Expression of CNTF/LIF-receptor
components and activation of STAT3 signaling in axotomized facial
motoneurons: evidence for a sequential postlesional function of the
cytokines. J Neurobiol 1999, 41:559–571.
65. Hasegawa T, Suzuki K, Sakamoto C, Ohta K, Nishiki S, Hino M, Tatsumi N,
Kitagawa S: Expression of the inhibitor of apoptosis (IAP) family members
in human neutrophils: up-regulation of cIAP2 by granulocyte colony-
stimulating factor and overexpression of cIAP2 in chronic neutrophilic
leukemia. Blood 2003, 101:1164–1171.
66. Cadet JL, Ordonez SV, Ordonez JV: Methamphetamine induces apoptosis
in immortalized neural cells: protection by the proto-oncogene, bcl-2.
Synapse 1997, 25:176–184.
doi:10.1186/1742-2094-9-103
Cite this article as: Coelho-Santos et al.: Prevention of
methamphetamine-induced microglial cell death by TNF-α and IL-6
through activation of the JAK-STAT pathway. Journal of
Neuroinflammation 2012 9:103.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Coelho-Santos et al. Journal of Neuroinflammation 2012, 9:103 Page 14 of 14
http://www.jneuroinflammation.com/content/9/1/103